Allergy diagnosis, allergen repertoires, and their implications for allergen-specific immunotherapy.
Immunotherapy for allergic diseases represents an important but largely unmet medical need. Conventional immunotherapy suffers from several breakdowns related to the quality of the extracts used, the risk of inducing anaphylactic reactions, and the extremely long treatment time. Many of the problems associated with using natural allergenic products for allergy diagnosis and treatment can be overcome using genetically engineered recombinant allergens. New therapeutic strategies based on recombinant technology include peptide-based vaccines, engineered hypoallergens with reduced IgE-binding properties, nucleotide-conjugated vaccines that promote Th1 responses, and the possibility of developing prophylactic allergen vaccines.
Crameri
Reto
R
Molecular Allergology, Swiss Institute of Allergy and Asthma Research (SIAF), Obere Strasse 22, CH-7270 Davos, Switzerland. crameri@siaf.unizh.ch
D000485:Allergens / Q000276:immunology*; D003888:Desensitization, Immunologic / Q000379:methods*; D006801:Humans; D006967:Hypersensitivity / Q000175:diagnosis* / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012882:Skin Tests; D014612:Vaccines
D000485:Allergens; D011994:Recombinant Proteins; D014612:Vaccines